Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).
Quartuccio N, Ialuna S, Scalisi D, D'Amato F, Barcellona MR, Bavetta MG, Fusco G, Bronte E, Musso E, Bronte F, Picciotto V, Carroccio A, Verderame F, Malizia G, Cistaro A, La Gattuta F, Moreci AM. Quartuccio N, et al. Among authors: verderame f. Curr Oncol. 2024 Mar 13;31(3):1504-1514. doi: 10.3390/curroncol31030114. Curr Oncol. 2024. PMID: 38534947 Free PMC article.
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Staropoli N, Geuna E, Rinaldi G, Bisagni G, Scotti V, Faggioni G, Vannini L, Arcara C, Moretti G, Gunnellini M, Coltelli L, Verderame F, Livi L, Sanna G, Grasso D, Abbinante G, Ragni F. Staropoli N, et al. Among authors: verderame f. Curr Oncol. 2022 Sep 17;29(9):6635-6641. doi: 10.3390/curroncol29090521. Curr Oncol. 2022. PMID: 36135090 Free PMC article.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Celsa C, Cabibbo G, Fulgenzi CAM, Scheiner B, D'Alessio A, Manfredi GF, Nishida N, Ang C, Marron TU, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro FR, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato DJ. Celsa C, et al. Among authors: verderame f. J Hepatol. 2024 Mar;80(3):431-442. doi: 10.1016/j.jhep.2023.10.040. Epub 2023 Nov 15. J Hepatol. 2024. PMID: 37972660 Free article.
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A. Cortinovis D, et al. Among authors: verderame f. Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590. Anticancer Res. 2019. PMID: 31366516 Clinical Trial.
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V, Valerio MR, Costa R, Tripoli V, Murabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C; members of the GSTU Foundation. Serretta V, et al. Among authors: verderame f. Urol Oncol. 2019 Dec;37(12):964-969. doi: 10.1016/j.urolonc.2019.08.009. Epub 2019 Oct 7. Urol Oncol. 2019. PMID: 31601517
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Among authors: verderame f. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. Conteduca V, et al. Among authors: verderame f. Future Oncol. 2015;11(21):2881-91. doi: 10.2217/fon.15.158. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26436290
Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes.
Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, De Gregorio G, Serretta V, Verderame F, Ognibene L, Lo Casto A, Ferrera G. Cuccia F, et al. Among authors: verderame f. Aging Clin Exp Res. 2020 Apr;32(4):747-753. doi: 10.1007/s40520-019-01243-1. Epub 2019 Jul 2. Aging Clin Exp Res. 2020. PMID: 31267377
61 results